Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap

Deal Expands Existing Cardiovascular Portfolio

 
• By Mandy Jackson
  
Business people working around M&A on wooden table
Analysts anticipate additional bolt-on deals for Merck • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business